LifeMD, Inc. (NASDAQ:LFMD) Shares Sold by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP cut its position in LifeMD, Inc. (NASDAQ:LFMD) by 11.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,498,382 shares of the company’s stock after selling 194,832 shares during the period. LifeMD accounts for 1.6% of Divisadero Street Capital Management LP’s holdings, making the stock its 16th largest position. Divisadero Street Capital Management LP owned about 3.59% of LifeMD worth $10,279,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. ClariVest Asset Management LLC lifted its holdings in LifeMD by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 91,967 shares of the company’s stock valued at $631,000 after purchasing an additional 2,600 shares in the last quarter. Quest Partners LLC purchased a new position in shares of LifeMD in the second quarter worth about $31,000. EntryPoint Capital LLC acquired a new position in LifeMD during the first quarter worth about $89,000. Los Angeles Capital Management LLC purchased a new stake in LifeMD during the 2nd quarter valued at about $88,000. Finally, XTX Topco Ltd acquired a new stake in LifeMD in the 2nd quarter valued at about $94,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

LifeMD Stock Up 0.8 %

Shares of NASDAQ LFMD opened at $5.28 on Friday. LifeMD, Inc. has a 1 year low of $4.05 and a 1 year high of $12.88. The company has a market capitalization of $220.48 million, a P/E ratio of -7.14 and a beta of 1.19. The company has a 50 day simple moving average of $5.74 and a 200-day simple moving average of $7.85. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.87 and a quick ratio of 0.83.

LifeMD (NASDAQ:LFMD) last posted its earnings results on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The business had revenue of $50.66 million during the quarter, compared to the consensus estimate of $48.47 million. During the same quarter in the prior year, the company earned ($0.23) EPS. On average, equities research analysts predict that LifeMD, Inc. will post -0.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LFMD has been the topic of several recent research reports. KeyCorp lowered their target price on LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a research note on Tuesday, August 20th. Finally, B. Riley began coverage on LifeMD in a report on Friday, August 23rd. They issued a “buy” rating and a $11.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.